VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Jeffrey Jones on Long-Term Outcomes With Ibrutinib in CLL

Jeffrey Jones, MD, MPH
Published: Monday, Aug 15, 2016


Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

For chemoimmunotherapy, researchers can estimate the long-term responses patients may or may not have. However, the same cannot be said for ibrutinib, as it is a newer agent in the field, Jones explains. For younger patients receiving ibrutinib, it is important to consider long-term toxicities that have yet to emerge, as well as treatment compliance.

This varies for patients depending on their age, as older patients may need to consider whether they would rather receive ibrutinib for an unprecedented amount of time versus 6 months of chemoimmunotherapy.

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

For chemoimmunotherapy, researchers can estimate the long-term responses patients may or may not have. However, the same cannot be said for ibrutinib, as it is a newer agent in the field, Jones explains. For younger patients receiving ibrutinib, it is important to consider long-term toxicities that have yet to emerge, as well as treatment compliance.

This varies for patients depending on their age, as older patients may need to consider whether they would rather receive ibrutinib for an unprecedented amount of time versus 6 months of chemoimmunotherapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x